BioMedNewsBreaks Archive - Page 2 of 242

TuesdayNov 11, 2025 10:45 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of their review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; https://doi.org/10.3390/ijms262210842). Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the paper is the first to comprehensively examine nanoparticles exclusively within the 5–15 nm range—an emerging scale poised to redefine nanomedicine. The review highlights how these sub-15 nm systems achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across…

MondayNov 10, 2025 3:11 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using the Ampa “one day” (ONE-D) protocol for treatment-resistant depression—the first deployment of its kind in Florida and among the first nationwide. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, which in peer-reviewed studies have shown response rates of 87% and remission rates of 72% in nonrandomized trials. Under the direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering the protocol, with six Florida locations expected by year-end.…

MondayNov 10, 2025 12:16 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across oncology Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer drug developer, is using large-scale machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications. CEO Panna Sharma told FintechTV the company’s proprietary platform now self-learns, reads scientific papers, models molecules, predicts patient response, and suggests new indications — significantly reducing the time and cost of drug development. Lantern has three clinical-stage oncology candidates, including a Phase 2 trial for…

FridayNov 07, 2025 3:29 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited,” said Dr. Sud Agarwal, CEO of Ingenu, a contract research organization in Australia. “We are proud…

FridayNov 07, 2025 10:05 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte(TM) study in cutaneous T-cell lymphoma (CTCL). CEO Christopher J. Schaber, PhD, confirmed that the first Data Monitoring Committee review found no safety concerns for HyBryte(TM), maintaining a consistent safety profile across trials. With $10.5 million in cash as of Sept. 30, 2025, Soligenix expects its operating runway to extend through 2026 while evaluating strategic options to…

ThursdayNov 06, 2025 12:05 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments

Lantern Pharma (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR(R) platform, will host a webcast at 9 a.m. ET (6 a.m. PT) on Thursday, Nov. 13, 2025, to review third-quarter operating and financial results. President and CEO Panna Sharma and other members of the management team will discuss quarterly performance, clinical trial progress, and upcoming milestones for the company’s AI and machine learning initiatives. To view the full press release, visit https://ibn.fm/yghCi About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and…

WednesdayNov 05, 2025 11:27 am

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) Subsidiary PharmcoRx Awarded Multi-State Prescription Fulfillment Contract From DevotedDOc

NextPlat (NASDAQ: NXPL, NXPLW), a global provider of healthcare and technology solutions through e-commerce and retail channels, announced that its PharmcoRx subsidiary has secured an exclusive multi-state prescription fulfillment services contract from DevotedDOc, a virtual medical group specializing in urgent care, Medication-Assisted Treatment for opioid use disorder, and compounded alternatives to GLP-1 therapies for weight loss and hormone replacement therapy. PharmcoRx will begin serving patients in Florida and Georgia in November, with plans to expand nationally across its licensed territories. Vice President of Healthcare Operations Birute Norkute said the partnership underscores NextPlat’s commitment to improving access to rapid, affordable, and…

WednesdayNov 05, 2025 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Initiated With Buy Rating and $4 Price Target by Roth Capital

HeartBeam (NASDAQ: BEAT) has been initiated with a Buy rating and $4 price target by Roth Capital Partners, which highlighted the company’s near-term catalyst of expected FDA clearance for its groundbreaking 12-lead ECG synthesis software. The report cites BEAT’s compact, credit card-sized, cable-free device capable of synthesizing a full 12-lead ECG as a breakthrough in remote cardiac monitoring. Roth’s analysts, led by Kyle Bauser, Ph.D., view BEAT as undervalued given its strong clinical validation, lean cost structure, and potential to redefine how arrhythmias are detected and treated in decentralized care environments. Roth’s initiation notes that HeartBeam’s pivotal VALID-ECG study (n=198)…

MondayNov 03, 2025 2:06 pm

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, will release its financial results for the quarter ended Sept. 30, 2025, before market open on Nov. 13, 2025. CEO and President of Global Operations David Phipps, CFO Amanda Ferrio, and Vice President of Healthcare Operations Birute Norkute will host a conference call that day at 8:30 a.m. ET to discuss the results and other recent developments. To view the full press release, visit: https://ibn.fm/9fSPg About NextPlat Corp. Nextplat is a global consumer products and services company providing healthcare…

FridayOct 31, 2025 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that Sapu Nano’s investigational intravenous Deciparticle(TM) everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, Dec. 9–12, 2025, in San Antonio, Texas. Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 is a novel Deciparticle(TM) formulation of everolimus designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, RCC, and NET. To view the full press release, visit https://ibn.fm/owoJh About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) Subsidiary PharmcoRx Awarded Multi-State Prescription Fulfillment Contract From DevotedDOc

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Initiated With Buy Rating and $4 Price Target by Roth Capital

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search